Notice2024-16027
Reorganization of the National Center for Immunization and Respiratory Diseases
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 22, 2024
Effective
July 17, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
CDC has modified its structure. This notice announces the reorganization of the National Center for Immunization and Respiratory Diseases (NCIRD). NCIRD has abolished offices, retitled divisions and branches, and modified mission and function statements.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 140 (Monday, July 22, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 140 (Monday, July 22, 2024)]
[Notices]
[Pages 59101-59104]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-16027]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Reorganization of the National Center for Immunization and
Respiratory Diseases
AGENCY: Centers for Disease Control and Prevention (CDC), the
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: CDC has modified its structure. This notice announces the
reorganization of the National Center for Immunization and Respiratory
Diseases (NCIRD). NCIRD has abolished offices, retitled divisions and
branches, and modified mission and function statements.
DATES: This reorganization of NCIRD was approved by the Director of CDC
on July 17, 2024 and became effective on July 17, 2024.
FOR FURTHER INFORMATION CONTACT: Rebecca Greco Kone, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, MS H24-9,
Atlanta, GA 30329; Telephone 800-232-4636; Email: <a href="/cdn-cgi/l/email-protection#d6a6bbb9b8b5bfa4b296b5b2b5f8b1b9a0"><span class="__cf_email__" data-cfemail="f2829f9d9c919b8096b2919691dc959d84">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Part C (Centers for Disease Control and
Prevention) of the Statement of Organization, Functions, and
Delegations of Authority of the Department of Health and Human Services
(45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296,
October 20, 1980, as amended most recently at 89 FR 56753, dated July
10, 2024) is amended to reflect the reorganization of National Center
for Immunization and Respiratory Diseases, Centers for Disease Control
and Prevention. Specifically, the changes are as follows:
I. Under Part C, Section C-B, Organization and Functions, make the
following changes:
<bullet> Update the Office of the Director (CJ1) mission/function
statements
<bullet> Abolish the Office of Informatics (CJ12)
<bullet> Abolish the Office of Policy (CJ13)
<bullet> Abolish the Office of Health Communications Science (CJ14)
<bullet> Abolish the Office of Management and Operations (CJ15)
<bullet> Abolish the Office of Science (CJ16)
<bullet> Abolish the Office of Global Health, Preparedness, and
Response (CJ17)
<bullet> Update the Division of Bacterial Diseases (CJE) mission/
function statements
<bullet> Retitle and update the mission/function statement for the
Respiratory
[[Page 59102]]
Disease Branch to the Pneumonia and Streptococcus Epidemiology Branch
(CJEB)
<bullet> Retitle and update the mission/function statement for the
Meningitis and Vaccine Preventable Disease Branch to the Meningitis,
Pertussis, and Diphtheria Epidemiology Branch (CJEC)
<bullet> Establish the Pneumonia and Streptococcus Laboratory Branch
(CJED)
<bullet> Establish the Meningitis, Pertussis, and Diphtheria Laboratory
Branch (CJEE)
II. Under Part C, Section C-B, Organization and Functions, within
the National Center for Immunization and Respiratory Diseases, delete
the mission or function statements for and replace with the following:
Office of the Director (CJ1). (1) provides leadership, expertise,
and service in laboratory and epidemiological sciences for respiratory
and vaccine-preventable diseases and in immunization program delivery;
(2) provides diagnostic and reference laboratory services to relevant
partnerships; (3) works with agency and other CIOs to ensure spending
plans, budget planning, and budget execution are in line with the
overall infectious disease strategies and priorities; (4) ensures that
NCIRD's strategy is executed by the divisions and aligned with overall
CDC goals, including leadership for and guidance for strategic planning
and performance measurement; (5) co-develops execution strategies for
NCIRD with the division directors;
(6) provides program and science quality oversight; (7) builds
leadership at the division and branch levels; (8) evaluates the
strategies, focus, and prioritization of the division research,
program, and budget activities; (9) identifies and coordinates
synergies between NCIRD and relevant partners; (10) ensures that policy
development is consistent and appropriate; (11) facilitates research
and program activities by providing leadership support; (12) proposes
resource priorities throughout the budget cycle; (13) ensures
scientific quality, ethics, and regulatory compliance; (14) fosters an
integrated approach to research, program, and policy activities; (15)
liaises with HHS and other domestic and international immunization and
respiratory disease partners, as well as with NCIRD divisions; (16)
coordinates center's emergency response activities related to
immunization issues and complex acute respiratory infectious disease
emergencies; (17) applies communication science, media principles, and
web design to support NCIRD and CDC's efforts to reduce morbidity and
mortality caused by vaccine-preventable and respiratory diseases;
ensuring that communication distributed by the center is timely,
accurate, clear and relevant to intended audiences; (18) provides
guidance for key scientific and laboratory services in the functional
areas of extramural research (research and non-research), human studies
oversight and review, regulatory affairs; activities in the areas of
space planning, advising, coordination and evaluation, safety
management and coordination, and shared services in controlled
correspondence, and programmatic services in the area of workforce and
career development; (19) provides and coordinates center-wide
administrative, management, and support services in the areas of fiscal
management, personnel, travel, procurement, facility management, and
other administrative services; (20) manages the coordination of
workforce development and succession planning activities, and provides
human capital management, planning, and training consultation services;
(21) develops and implements a coordinated healthcare provider strategy
across NCIRD programs that maximizes public health outcomes; (22)
directs the cultivation of clinical partnerships aimed at enhancing the
reach and effectiveness of NCIRD programs; (23) leads the coordination
and guidance of Advisory Committee on Immunization Practices (ACIP)
related work; (24) designs and operationalize s cross-cutting public
health strategies that improve outcomes for high risk groups; (25)
provides advice to NCIRD leadership in developing policies, programs,
implementation guidance, and strategic initiatives; (26) works with
NCIRD programs, other CIOs, and agency to ensure NCIRD programs and
priorities are incorporated into priority initiatives; (27) monitors
and evaluates effectiveness of strategic plans and priorities,
including linkages of resources to priorities and identification of
public health outcomes to track effectiveness; (28) provides strategic
guidance and direction, technical assistance and support for NCIRD's
health equity portfolio; (29) tracks progress towards advancing health
equity in the areas of science, intervention, and partnerships as
aligned with CDC's CORE Health Equity framework; (30) advises NCIRD and
CDC leadership on global health related to current and known
respiratory threats and to emerging respiratory pandemic threats; (31)
provides strategic leadership for NCIRD in the areas of global health
related to respiratory and vaccine-preventable diseases, including
establishing NCIRD priorities, promoting science, policies, and new
programs; (32) coordinates NCIRD efforts related to funding and budgets
for global health security; and (33) supports NCIRD's work across CDC
and the federal government on global health security, respiratory
diseases.
Division of Bacterial Diseases (CJE). The mission of the Division
of Bacterial Diseases (DBD) is to prevent and control illness and death
from vaccine-preventable and other respiratory bacterial diseases, in
the United States and worldwide, through leadership in epidemiologic
and laboratory science and vaccine policy. DBD's cross-cutting
functions include laboratory science, epidemiologic science, vaccine
science, and partner support. (1) Provides laboratory support for
surveillance and epidemiologic studies and reference diagnostic
services to state, tribal, local, and territorial health departments,
other federal agencies, and national and international health
organizations; (2) develops, analyzes, and improves diagnostic methods
and reagents; (3) facilitates development and evaluation of immunologic
compounds, and vaccines; (4) conducts laboratory studies of the
biological, biochemical, genetic, and antigenic characteristics,
immunology, and pathogenesis of disease; (5) participates in and
supports investigations of outbreaks, clusters, epidemics, and other
public health problems in the United States and internationally, and
recommends and evaluates appropriate control measures; (6) conducts
surveillance for bacteria under the division's purview, including
surveillance for antimicrobial resistance; assists state, tribal,
local, and territorial health departments with conducting surveillance;
prepares and distributes surveillance information; (7) conducts
epidemiologic studies to define etiology, patterns of disease, disease
burden, and risk factors; (8) provides consultation on the use of
bacterial vaccines and other measures to prevent infections; identifies
and evaluates other (non-vaccine) prevention strategies; and evaluates
other aspects of vaccination practices; (9) determines the
effectiveness and cost effectiveness of vaccines through the evaluation
of scientific evidence; (10) supports the development and evaluation of
vaccination policy and programs, and helps prepare statements on
bacterial vaccines for ACIP and other groups in the United States; (11)
[[Page 59103]]
provides guidance and technical expertise on vaccine-preventable
disease policy development in international settings; (12) supports
CDC's Immunization Safety Office in vaccine safety risk assessment and
leadership in vaccine safety risk management; (13) advises the World
Health Organization (WHO) on global vaccine policies and strategies via
the Strategic Advisory Group of Experts on Immunization; (14) provides
technical support to state immunization programs for all aspects of
vaccine-preventable diseases and their vaccines; (15) assists internal
and external partners with other public health problems of national and
international significance when needed; and (16) provides assistance
with professional training for both internal and external partners.
Office of the Director (CJE1). (1) directs, coordinates, and
manages the programs and activities of the division; (2) provides
leadership and guidance on scientific strategy, policy, communications,
partnerships, program planning and development, program management, and
operations; (3) coordinates or assures coordination with the
appropriate CDC and NCIRD offices on administrative and program
matters; (4) reviews, prepares, and coordinates congressional testimony
and briefing documents related to bacterial respiratory and vaccine-
preventable diseases, and analyzes programmatic and policy implications
of legislative proposals; (5) serves as CDC and NCIRD's primary
internal and external communications contact regarding bacterial
respiratory and vaccine-preventable disease issues; (6) advises CDC and
NCIRD on policy and communications matters concerning the division's
programs and activities; (7) assures the overall quality and integrity
of the science conducted by the division; (8) coordinates division
activities on cross-cutting agency initiatives; (9) guides and
coordinates with division laboratory branches to implement quality
management systems and maintain safety; (10) guides and facilitates
efficient coordination and cooperation for administrative,
programmatic, and scientific activities within the division, and with
other groups in and outside of CDC; (11) provides statistical
consultation for epidemiologic and laboratory research studies
conducted by the division, including developing new methods for
statistical applications; and (12) provides overall leadership,
guidance, support, and coordination for the division's global health
activities.
Pneumonia and Streptococcus Epidemiology Branch (CJEB). (1)
provides epidemiologic subject matter expertise and technical
assistance for surveillance, prevention and control of respiratory and
other syndromes caused by Streptococcus pneumoniae, group A and group B
streptococci, and atypical respiratory bacteria (Legionella,
Mycoplasma, and Chlamydia species), including outbreaks and
antimicrobial-resistant infections, as well as community-acquired
pneumonia, otitis media, and neonatal sepsis; (2) conducts surveillance
and epidemiologic research for these diseases; (3) develops,
implements, and evaluates prevention methods for these diseases,
including vaccine and non-vaccine strategies; (4) supports development
of vaccine policy through the ACIP process; (5) provides consultation
and support to domestic and international partners on the use of
vaccines and other prevention measures for bacterial respiratory
diseases; (6) coordinates activities within and outside the division
related to Active Bacterial Core surveillance with the Emerging
Infections Program sites, and leverages other surveillance platforms
that include bacterial respiratory diseases; and (7) collaborates with
other CDC groups, other federal agencies, state, tribal, local, and
territorial groups, ministries of health, WHO, private industry,
academia, and other governmental and non-governmental organizations
involved in public health.
Meningitis, Pertussis, and Diphtheria Epidemiology Branch (CJEC).
(1) provides laboratory subject matter expertise and technical
assistance for surveillance, prevention, and control of bacterial
illness, including meningococcal disease, Haemophilus influenzae
disease, diphtheria, pertussis, tetanus, and bacterial meningitis
syndrome; (2) provides reference and diagnostic testing support for
agents causing these diseases; (3) develops and evaluates new
diagnostic methods for these bacterial pathogens; (4) develops,
maintains, and implements genomic analyses of bacteria to enhance
surveillance programs, outbreak investigations, and public health
research; (5) provides leadership and expertise for the study of
immunologic response to infection, vaccination, and therapeutic
interventions against bacterial respiratory diseases; (6) ensures that
the laboratory quality management system functions according to CDC
policy and other regulatory requirements, e.g., Clinical Laboratory
Improvement Amendments (CLIA); maintains laboratory safety practices
and provides guidance to ensure a safe work environment; (7)
collaborates with other CDC groups; other federal agencies; state,
tribal, local, and territorial groups; ministries of health; WHO;
private industry; academia; and other governmental and non-governmental
organizations involved in public health; and (8) maintains World Health
Organization Collaborating Center for Control and Prevention of
Epidemic Meningitis.
Pneumonia and Streptococcus Laboratory Branch (CJED). (1) provides
laboratory subject matter expertise and technical assistance for
surveillance, prevention, and control of respiratory and other
syndromes caused by Streptococcus pneumoniae, group A and group B
streptococci, and atypical respiratory bacteria (Legionella,
Mycoplasma, and Chlamydia species), including outbreaks and
antimicrobial-resistant infections, as well as community-acquired
pneumonia, otitis media, and neonatal sepsis; (2) provides reference
and diagnostic testing support for bacterial respiratory diseases and
for the identification of unknown gram-positive cocci; (3) develops and
evaluates new diagnostic methods for bacterial respiratory pathogens;
(4) develops, maintains, and implements genomic analyses of bacteria to
enhance surveillance programs, outbreak investigations, and public
health research; (5) maintains the World Health Organization
Collaborating Center for Streptococcal Infections; (6) ensures that the
laboratory quality management system functions according to CDC policy
and other regulatory requirements, e.g., CLIA; maintains laboratory
safety practices and provides guidance to ensure a safe work
environment; and (7) collaborates with other CDC groups; other federal
agencies; state, tribal, local, and territorial groups; ministries of
health; WHO; private industry; academia; and other governmental and
non-governmental organizations involved in public health.
Meningitis, Pertussis, and Diphtheria Laboratory Branch (CJEE). (1)
provides laboratory subject matter expertise and technical assistance
for surveillance, prevention, and control of bacterial illness,
including meningococcal disease, Haemophilus influenzae disease,
diphtheria, pertussis, tetanus, and bacterial meningitis syndrome; (2)
provides reference and diagnostic testing support for agents causing
these diseases; (3) develops and evaluates new diagnostic methods for
these bacterial pathogens; (4) develops, maintains, and implements
genomic analyses of bacteria to enhance surveillance programs, outbreak
investigations, and public health
[[Page 59104]]
research; (5) provides leadership and expertise for the study of
immunologic response to infection, vaccination, and therapeutic
interventions against bacterial respiratory diseases; (6) ensures that
the laboratory quality management system functions according to CDC
policy and other regulatory requirements, e.g. CLIA; maintains
laboratory safety practices and provides guidance to ensure a safe work
environment; (7) collaborates with other CDC groups; other federal
agencies; state, tribal, local, and territorial groups, ministries of
health, WHO, private industry, academia, and other governmental and
non-governmental organizations involved in public health; and (8)
maintains World Health Organization Collaborating Center for Control
and Prevention of Epidemic Meningitis.
Delegations of Authority
All delegations and redelegations of authority made to officials
and employees of affected organizational components will continue in
them or their successors pending further redelegation, provided they
are consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Robin D. Bailey,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-16027 Filed 7-19-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 22, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.